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ORIGINAL INVESTIGATION
Heart failure and the prognostic impact 
and incidence of new-onset of diabetes 
mellitus: a nationwide cohort study
B. Zareini1*, Rasmus Rørth2, Anders Holt1, Ulrik M. Mogensen2, Christian Selmer3, Gunnar Gislason1, 
Morten Schou1, Lars Køber2, Christian Torp‑Pedersen4,5, Morten Lamberts1 and Søren Lund Kristensen2
Abstract 
Background: Prevalent diabetes at the time of heart failure (HF) diagnosis is associated with a higher risk of death, 
but the incidence and prognostic importance of new‑onset diabetes in patients with established HF remains 
unknown.
Methods: Patients with a first hospitalization for HF in the period 2003–2014 were included and stratified according 
to history of diabetes. Annual incidence rates of new‑onset diabetes were calculated and time‑dependent multivaria‑
ble Cox regression models were used to compare the risk of death in patients with prevalent and new‑onset diabetes 
with patients without diabetes as reference. The model was adjusted for age, sex, duration of HF, educational level and 
comorbidity. Covariates were continuously updated throughout follow‑up.
Results: A total of 104,522 HF patients were included in the study, of which 21,216 (19%) patients had diabetes 
at baseline, and 8164 (10%) developed new‑onset diabetes during a mean follow‑up of 3.9 years. Patients with 
new‑onset diabetes and prevalent diabetes were slightly younger than patients without diabetes (70 vs. 74 and 77, 
respectively), more likely to be men (62% vs. 60% and 54%), and had more comorbidities expect for ischemic heart 
disease, hypertension and chronic kidney disease which were more prevalent among patients with prevalent diabe‑
tes. Incidence rates of new‑onset diabetes increased from around 2 per 100 person‑years in the first years following 
HF hospitalization up to 3 per 100 person‑years after 5 years of follow‑up. A total of 61,424 (59%) patients died during 
the study period with event rates per 100 person‑years of 21.5 for new‑onset diabetes, 17.9 for prevalent diabetes and 
13.9 for patients without diabetes. Compared to patients without diabetes, new‑onset diabetes was associated with a 
higher risk of death (adjusted HR 1.47; 95% CI 1.42–1.52) and prevalent diabetes was associated with an intermediate 
risk (HR 1.19; 95% CI, 1.16–1.21).
Conclusion: Following the first HF hospitalization, the incidence of new‑onset diabetes was around 2% per year, ris‑
ing to 3% after 5 years of follow‑up. New‑onset diabetes was associated with an increased risk of death, compared to 
HF patients with prevalent diabetes (intermediate risk) and HF patients without diabetes.
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Background
Heart failure (HF) and diabetes frequently co-exist and 
in the most contemporary trials of heart failure, one out 
of three patients had a history of diabetes [1]. Hypergly-
cemia has been associated with changes in cardiac struc-
ture, cardiac function, increased atherosclerosis, and the 
existence of a specific diabetic cardiomyopathy pheno-
type has been suggested [2–4]. Conversely, HF has been 
associated with insulin resistance and hyperglycemia in 
a severity-dependent manner [5–7]. Despite previous 
studies establishing the detrimental prognosis of patients 
with HF and diabetes, the interplay of this bidirectional 
relationship has not been fully elucidated Specifically, 
the mortality risk associated with new-onset diabetes vs. 
prevalent diabetes in patients with HF has never been 
investigated. Our purpose was to investigate the inci-
dence of new-onset diabetes following a diagnosis of HF 
and compare its prognostic impact on the risk of death 
with that of HF patients with prevalent diabetes and 
without diabetes.
Methods
Data sources
In Denmark, every resident is assigned a unique personal 
identification number enabling individual-level linkage 
between nationwide health care registries. The Dan-
ish National Patient Registry entails information on all 
hospital admissions from 1978 and forward. Each hos-
pital contact is coded with a primary diagnosis and sev-
eral secondary diagnoses according to The International 
Classification of Disease, Eighth Revision (ICD-8) until 
1993, and The International Classification of Disease, 
Tenth Revision (ICD-10) from 1994 onwards. The Danish 
National Prescription Registry holds information (dos-
age, dates, and Anatomical Therapeutic Chemical (ATC) 
codes on all prescriptions dispensed from a pharmacy 
since 1995 and the Danish Civil Registration System 
records vital-status.
Study population
We included adults (older than 18  years) with a first-
time diagnosis of HF in hospital discharge records in the 
period 2003–2014. The index date (date of inclusion) was 
30 days after discharge from the hospital.
Definition of diabetes status
Prevalent diabetes was defined by at least one prescrip-
tion of a glucose-lowering drug and/or a previous ICD 
code of diabetes 6 months prior to the index date. New-
onset diabetes was defined by a first claimed prescrip-
tion of a glucose-lowering drug and/or an ICD code of 
diabetes after index date in patients with no prior his-
tory of diabetes. Combining the use of ICD codes and 
prescriptions to assess diabetes status have been vali-
dated previously with a positive predictive value of 97% 
and 95%, respectively [8–10].
Definition of comorbidities and medical therapy
Comorbidities were identified through ICD codes 
from hospital records up to 10  years prior to the index 
date, and continuously updated throughout the follow-
up period (see Appendix: Table  2 for details and ICD 
codes). Information on concomitant medical therapy was 
obtained from dispensed prescriptions as listed in the 
Danish National Prescription Registry and defined by at 
least one redeemed prescription of the drug 6  months 
prior to the index date. The following drugs were 
recorded at inclusion baseline: angiotensin-converting 
enzyme inhibitors (ACE), angiotensin II receptor block-
ers (ARB), calcium channel blockers, loop diuretics, 
thiazides, digoxin, platelet inhibitors (acetylic acid and 
adenosine diphosphate receptor inhibitor), mineralocor-
ticoid receptor antagonists (MRA), statins, beta-block-
ers, insulin, metformin, sulfonylurea, thiazolidinedione 
(TZD), dipeptidyl peptidase-4 (DPP-4) inhibitor, gluca-
gon-like peptide-1 (GLP-1) receptor agonist, sodium-glu-
cose cotransporter-2 (SGLT2) inhibitor and patients who 
treated with a combination of two anti-diabetic drugs. 
DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 
inhibitors were combined in one group defined as newer 
antidiabetic medication for further statistical analysis 
(see Appendix: Table  2 on details regarding details and 
ATC codes).
Outcome measures
The outcomes of the study were new-onset diabetes and 
all-cause death. Patients were followed to new-onset dia-
betes, death, emigration or end of study (31 December 
2015).
Statistics
Baseline characteristics were described by the use 
of proportions for categorical variables with means 
and standard deviations (SD) or medians and inter-
quartile ranges (IQR) for continuous variables. Dif-
ferences between groups were tested by use of the 
Chi square test for categorical variables, non-para-
metric test for non-normally distributed continuous 
variables and parametric for normally distributed 
continuous variables. Annual incidence rates of new-
onset diabetes were calculated per 100 person-years. 
In analyses of all-cause death, we treated new-onset 
diabetes as a time-dependent variable and com-
pared the risk with prevalent diabetes patients and 
patients free of diabetes as reference. To account 
for the longer duration of HF in patients with 
Page 3 of 10Zareini et al. Cardiovasc Diabetol           (2019) 18:79 
new-onset diabetes, follow-up time was split into 
1-year intervals from inclusion date, and according 
to calendar year in 3-year intervals. These variables 
were included in the adjusted model. Comorbid-
ity and antidiabetic medication were continuously 
updated throughout follow-up, and age was updated 
at the beginning of each interval. A multivariable 
Cox proportional hazards analysis was performed 
to compare hazard ratios of death according to dia-
betes status. The model was adjusted for age, sex, 
duration of HF, education level and each individual 
comorbidity (ischemic heart disease, cancer, atrial 
fibrillation, chronic obstructive pulmonary disease, 
chronic kidney disease, hypertension, and stroke). To 
compare new-onset diabetes to prevalent diabetes, 
we repeated the analysis, but used prevalent diabe-
tes status as the reference and included antidiabetic 
medication (metformin, insulin, TZD, sulfonylurea 
and newer anti-diabetic drugs consisting of DPP-4 
inhibitors, SGLT2-inhibitors, and GLP-1 receptor 
agonists) in the model. Tests for interactions of dia-
betes status and sex in relation to risk of death were 
performed. Analyses were performed using SAS (ver-
sion 9.4 for Windows, SAS Institute, North Carolina) 
and R (version 3.5.0 for Windows, R Foundation for 
Statistical Computing) [11].
Results
Of 104,522 HF patients included in the study, 21,216 
(19%) patients had diabetes at baseline, and 8164 (10%) 
patients without diabetes at baseline developed new-
onset diabetes during the follow-up period (Fig.  1). 
Patient characteristics of all three groups are shown 
in Table 1 (with the baseline for the new-onset diabe-
tes group being time of diabetes diagnosis). Patients 
with new-onset diabetes and prevalent diabetes were 
slightly younger than patients without diabetes (70 vs. 
74 and 77, respectively), more likely to be men (62% 
vs. 60% and 54%), and had more comorbidities except 
for ischemic heart disease, hypertension and chronic 
kidney disease which were more present in patients 
with prevalent diabetes All evaluated pharmacother-
apy, including evidence-based HF medication was 
more widely used among patients with prevalent dia-
betes than in patient with new-onset or no diabetes 
except for beta blockers (68% vs. 63% vs.  %), digoxin 
(34% vs. 22% vs. 24%) and MRA (32% vs. 28% vs. 23%) 
which were more likely to be given to patients with 
new-onset diabetes. Patients with prevalent diabetes 
were more likely to be treated with all types of anti-
diabetic medications except for metformin which was 
more likely to be prescribed to patients with new-
onset diabetes (54% vs. 44%). The comparisons are at 
Fig. 1 Flowchart. Flowchart of the study cohort showing inclusion and exclusion of patients. HF heart failure, DM diabetes, N number
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least, partly skewed by the fact that baseline for the 
new-onset diabetes was after a mean HF duration of 
3.2  years as compared to the time of HF diagnosis in 
the two other groups. 
New‑onset diabetes
During a mean follow-up of 3.9  years, 8164 (10%) 
developed new-onset diabetes yielding an event rate of 
2.5 per 100 person-years. Over time, annual incidence 
rates of new-onset diabetes increased from around 2 
per 100 person-years in the first years following HF 
hospitalization up to 3 per 100 person-years after 
5 years of follow-up (Fig. 2).
All‑cause death
A total of 61,424 (59%) patients died during the study 
period, with an event rate of 15.0 per 100 person-years. 
Rates were lowest among patients without diabe-
tes (13.9 per 100 person-years), intermediate in those 
with prevalent diabetes (17.9 per 100 person-years) 
and highest among patients with new-onset diabetes 
(21.5 per 100 person-years). In age- and sex-adjusted 
analyses this yielded hazard ratios (HR) of 1.46 (95% CI 
1.43–1.49) for prevalent diabetes and HR 1.86 (95% CI 
Table 1 Patient characteristics of HF patients at inclusion according to diabetes
DM diabetes mellitus, IQR interquartile range, IHD ischemic heart disease, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, ACE angiotensin 
inhibitor medication, ARB angiotensin II receptor blockers, MRA mineralocorticoid receptor antagonists, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, 
SGLT2 sodium-glucose-cotransporter-2
* All cancers, excluding non-melanoma skin cancers
Variable No diabetes Prevalent diabetes New‑onset diabetes Total p‑value
Number of individuals 75,142 21,216 8164 104,522
Age (median with IQR) 77.0 (18.0, 109.0) 74.0 (22.0, 103.0) 70.0 (18.0, 100.0) 76.0 (18.0, 109.0) < 1e−04
Comorbidities
 Sex 40,733 (54.2) 12,726 (60.0) 5056 (61.9) 58,515 (56.0) < 1e−04
 IHD 40,621 (54.1) 14,071 (66.3) 5272 (64.6) 59,964 (57.4) < 1e−04
 Atrial fibrillation 36,133 (48.1) 9848 (46.4) 4634 (56.8) 50,615 (48.4) < 1e−04
 Cancer* 18,323 (24.4) 4850 (22.9) 2021 (24.8) 25,194 (24.1) < 1e−04
 COPD 20,575 (27.4) 6532 (30.8) 2834 (34.7) 29,941 (28.6) < 1e−04
 Hypertension 37,862 (50.4) 15,499 (73.1) 5497 (67.3) 58,858 (56.3) < 1e−04
 CKD 11,521 (15.3) 6193 (29.2) 1886 (23.1) 19,600 (18.8) < 1e−04
Pharmacotherapy
 Statin 27,578 (36.7) 13,242 (62.4) 4967 (60.8) 45,787 (43.8) < 1e−04
 ACE/ARB 47,434 (63.1) 16,246 (76.6) 5497 (67.3) 69,177 (66.2) < 1e−04
 Beta blockers 44,446 (59.1) 13,437 (63.3) 5522 (67.6) 63,405 (60.7) < 1e−04
 Digoxin 17,873 (23.8) 4687 (22.1) 2731 (33.5) 25,291 (24.2) < 1e−04
 ADP 44,409 (59.1) 14,943 (70.4) 4834 (59.2) 64,186 (61.4) < 1e−04
 Loop diuretics 53,114 (70.7) 16,764 (79.0) 5763 (70.6) 75,641 (72.4) < 1e−04
 MRA 17,211 (22.9) 5991 (28.2) 2635 (32.3) 25,837 (24.7) < 1e−04
 Thiazide 15,222 (20.3) 4316 (20.3) 989 (12.1) 20,527 (19.6) < 1e−04
 Ca channel blockers 17,478 (23.3) 7403 (34.9) 1843 (22.6) 26,724 (25.6) < 1e−04
 Insulin 6999 (33.0) 825 (10.1) 7824 (7.5) < 1e−04
 Metformin 9340 (44.0) 4425 (54.2) 13,765 (13.2) < 1e−04
 Sulfonylurea 6859 (32.3) 1239 (15.2) 8098 (7.7) < 1e−04
 Thiazolidinedione 82 (0.4) 5 (0.1) 87 (0.1) < 1e−04
 DPP‑4 inhibitors 574 (2.7) 264 (3.2) 838 (0.8) < 1e−04
 GLP‑1 receptor agnoists 1 (0.0) 28 (0.3) 29 (0.0) < 1e−04
 SGLT2 inhibitors 1 (0.0) 8 (0.1) 9 (0.0) < 1e−04
 Newer antidiabetic drugs: 
DPP‑4, GLP‑1 and SGLT2 
combined
576 (0.5) 294 (0.3) 870 (0.8) < 1e−04
 Combination of two antidia‑
betic drugs
427 (2.0) 78 (1.0) 505 (0.5) < 1e−04
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1.78–1.91) for new-onset diabetes with patients with 
HF and no diabetes as reference. In adjusted analyses 
additionally including education level, and continu-
ously updated duration of HF and comorbidity, the risk 
estimates were somewhat lower with HR 1.19 (95% CI 
1.16–1.21) for prevalent diabetes and HR 1.47 (95% CI 
1.42–1.52) for new-onset diabetes  (Fig.  3). Including 
antidiabetic medication (metformin, insulin, sulfony-
lurea, and newer anti-diabetic drugs) and comparing 
prevalent diabetes patients directly with new-onset dia-
betes patients in the adjusted model, we found a signifi-
cantly higher risk estimate for patients with new-onset 
diabetes HR 1.24 (95% CI 1.20–1.29). We found no 
interaction between diabetes status and sex in relation 
to the risk of all-cause death (p = 0.229).
Discussion
In this nationwide cohort study including more than 
100,000 patients with HF on the impact of prevalent and 
new-onset diabetes, we have two key findings: First, the 
annual incidence of new-onset diabetes was approxi-
mately 2% in the first years after HF diagnosis and ris-
ing to around 3% after 5  years of HF duration. Second, 
HF patients with new-onset diabetes had a markedly 
elevated risk of death, compared to HF patients without 
diabetes and with intermediate risk in HF patients with 
prevalent diabetes.
Relationship between diabetes and development of HF
The association between diabetes and HF has been well 
established and reproduced in several observational 
cohorts. Diabetes is associated with an up to four times 
increased risk of HF when compared to a general popula-
tion without diabetes [12]. It is not clear whether this is 
due to shared risk factors for the two conditions or the 
presence of a specific diabetic cardiomyopathy, where 
pathophysiological mechanisms related to abnormal car-
diac handling of glucose has been suggested to lead to 
both systolic and diastolic dysfunction [4, 13]. The high 
incidence of HF in patients with diabetes, even when 
coronary artery disease is absent, suggests a substan-
tial direct relation between diabetes and development 
of HF [13]. The higher mortality associated with preva-
lent diabetes in this study correlates with previous stud-
ies describing diabetes as an independent risk factor for 
death and adverse cardiovascular outcomes in patients 
with HF [1, 12, 14–17]. Obesity is closely related to diabe-
tes and its presence in patients with diabetes is associated 
with an increased risk of developing HF, but surpris-
ingly reduced mortality [18]. In established HF, this so-
called obesity paradox of reduced mortality exists for 
patients without diabetes but was not found in patients 
with diabetes [19]. Our finding of a poorer prognosis in 
HF patients with incident diabetes is in line with a prior 
study which showed a graded relation between blood 
Fig. 2 Annual incidence rates of new‑onset DM per 100 py of follow‑up. The annual crude incidence rates of patients with HF and new‑onset 
diabetes with error bars indicating 95% confidence interval
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glucose levels at the time of hospitalization for HF and 
long-term outcomes in patients without known diabetes 
[20]. An older study using Danish registry data showed 
that mortality risk in HF patients was lower in women, 
but we found no interaction between diabetes status, sex 
and mortality risk in the present analysis [21].
Prevalent HF and diabetes
The stepwise increase in the incidence of diabetes as 
HF persists in our study is consistent with the hypoth-
esis that HF over time can lead to diabetes. Apart from 
including real-world patients, our study highlights 
important information on how the annual incidence 
changes over time and similar to that reported from clini-
cal trials [22–25]. Several studies have shown that insulin 
sensitivity decreases as HF progresses. In the Bezafibrate 
Infarction Prevention study development of diabetes 
among HF patients occurred in a stepwise manner from 
13% in New York Heart Association (NYHA) Class I 
to 20% in NYHA Class III during a mean follow-up of 
7.7 years. Being in NYHA Class III was an independent 
risk factor for the development of diabetes [26]. Further-
more in patients with advanced HF, left ventricular assist 
device implantation have been shown to improve diabe-
tes control [27]. In this cohort of real-life patients with 
HF, around 10% of patients without diabetes at baseline, 
developed new-onset diabetes during follow-up, which 
is similar to findings from the Carvedilol Or Metoprolol 
European Trial (COMET) where around 10–12% devel-
oped diabetes during 5  years of follow-up [22]. Prior 
observational studies have demonstrated that increasing 
HF severity (as defined by dosages of loop diuretics) is 
associated with new-onset diabetes in a severity-depend-
ent manner [7, 28]. The decreased cardiac output as seen 
in progressive HF may lead to diminished oxygen, glu-
cose and insulin distribution to peripheral muscular tis-
sue as well as a loss of muscle mass which in turn may 
increase insulin resistance [29]. Impaired blood flow 
can increase systemic levels of adrenaline (epinephrine) 
and noradrenaline (norepinephrine) which is suggested 
to increase insulin resistance and hepatic gluconeogen-
esis as well as decrease the insulin release from pan-
creatic beta cells. Sympathetic overdrive has also been 
shown to reduce insulin sensitivity [5, 30]. This relation 
between HF and incident diabetes has been supported by 
observational studies [7, 26]. The bidirectional relation-
ship between diabetes and HF is supported by several 
clinical and epidemiological studies, but the causality 
remains unclear. The idea of a common disease origin, 
in a recent review, proposes inflammation and oxida-
tive stress could be the common ground for the develop-
ment of both diabetes and cardiovascular disease [31]. 
Targeted anti-inflammatory therapy decreased the risk of 
recurrent cardiovascular events in patients with known 
cardiovascular disease and several studies showed novel 
genetic variants linked to increased risk of both diabetes 
and cardiovascular disease development [32–34].
Antidiabetic medication and cardiovascular risk
As expected, patients with new-onset diabetes were 
not primarily prescribed insulins, thiazolidinediones or 
DPP-4 inhibitors as these drugs are usually used as add-
ons with the progression of diabetes. Only rarely insulin 
is used as first-line treatment in patients diagnosed with 
severely dysregulated diabetes. Likewise, among patients 
with prevalent diabetes, we found a higher prevalence 
of all types of antidiabetic drugs, as these patients have 
had their diabetes for a longer period and therefore often 
require second-line antidiabetics. In our crude analysis, 
the risk of death among patients with new-onset diabe-
tes was significantly different and attenuated compared 
to patients with prevalent diabetes and no diabetes. After 
adjustment for age, sex, duration of HF, baseline comor-
bidities and antidiabetic medication, the risk was higher 
among patients with new-onset diabetes. The cardiovas-
cular safety profile for antidiabetic drugs in patients has 
been questioned. Overly aggressive antidiabetic therapy 
may lead to hypoglycemia, and both insulin, as well as 
thiazolidinediones, can lead to fluid retention and wors-
ening of HF [13, 35]. Compared to SGLT2 inhibitors 
DPP-4 inhibitors were associated with increased risk of 
HF hospitalization [36]. The small number of patients 
receiving SGLT2 inhibitors and GLP-1 inhibitors within 
our cohort limits us in terms of assessing the impact of 
these drugs. But, the increased risk in patients with new-
onset diabetes after adjustment for antidiabetic medi-
cation and comorbidity status could be suggestive of an 
association that is not fully explained by the uncertain 
safety profile of antidiabetic medication nor the increased 
comorbidities among patients with new-onset diabetes. 
Our study underlines the need to further explore risk fac-
tors associated with the development of new-onset dia-
betes in HF patients.
Limitations
The main limitations of the present study is the lack of 
information on clinical variables reflecting HF and dia-
betes severity including ejection fraction, NYHA class 
and smoking status, vital parameters e.g. heart rate and 
blood pressure, body mass index, biochemical param-
eters such as natriuretic peptides (e.g. NT-pro-BNP), glu-
cose levels, hemoglobin A1c and type of diabetes. As we 
were not able to fully adjust for these possible confound-
ers, residual bias cannot be ruled out. Secondary we lack 
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information on diet treated diabetes patients, which con-
fers a selections bias towards a more ill cohort than in the 
general population.
Clinical implications
We have shown the impact on prognosis development 
of new-onset diabetes in patients with HF compared 
to patients without diabetes. Around 10% of the HF 
cohort developed new-onset diabetes and the incidence 
of new-onset diabetes was rising during follow-up aid-
ing important information from a real-world cohort. 
We hope our findings will aid clinicians in assessing 
important subgroups among patients with HF in need 
of close monitoring and supervision of co-existing dia-
betes illness.
Conclusion
Development of new-onset diabetes is common after first 
HF hospitalization and associated with an increased risk 
of death compared with HF patients with prevalent as 
well as no diabetes. Our study underlines the close and 
detrimental correlation between HF and diabetes and 
further studies are needed to explore the potential ben-
efit of early diagnosis and improved management of dia-
betes in the setting of concomitant HF.
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Appendix
See Table 2.
Table 2 Diagnoses (primary or  secondary), surgical procedures, and  pharmacotherapy used for  defining the  study 
population, comorbidity, concomitant treatment, and outcomes
Diagnoses (primary or secondary), surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, concomitant treatment, and 
outcomes
ATC: Anatomical Therapeutic Chemical (ATC) system; ICD-8: 8th revision of the International Classification of Diseases system; ICD-10: 10th revision of the International 
Classification of Diseases system
Details ICD‑8, ICD‑10, and ATC codes used
Study population
 Heart failure Defined from diagnosis codes including heart failure, cardiomyo‑
pathies, hypertensive heart failure
ICD‑10: I110, I130, I132, I42, I426‑29, I50
ICD‑8: 425, 428
Diabetes Defined from treatment with glucose‑lowering drugs ATC: A10
Comorbidity
 Diabetes ICD‑10: E10‑E14
ICD‑8: 250
 Stroke ICD‑10: I60‑I64
ICD‑8: 430‑434, 436
 Ischemic heart disease ICD‑10: I21‑25
ICD‑8: 410‑414
 Chronic kidney disease Defined from diagnosis codes of chronic glomerulonephritis, 
chronic tubulointerstitial nephropathy, chronic kidney disease, 
and diabetic and hypertensive nephropathy.
ICD‑10: N02‑N04, N18‑N19, I12, I13
ICD‑8: 582‑6, 588
 Atrial fibrillation ICD‑10: I48
42,793, 42,793
 Cancer Defined from all cancer diagnosis codes, excluding non‑melanoma 
skin cancer
ICD‑10: C00‑C97
ICD‑8: 140‑209
 Chronic obstructive pulmonary disease ICD‑10: J42, J44
ICD‑8: 490–492
 Hypertension ICD 10: I10‑I15
ICD‑8: 400‑404
Concomitant pharmacotherapy
 Statins ATC: C10A
 Beta‑blockers ATC: C07
 Aldosterone antagonists ATC: CO3D
 Platelet inhibitors ATC: B01AC04, BO1AC06
 Digoxin ATC: C01AA05
 Thiazides ATC CO3A
 Renin angiotensin system inhibitors Including angiotensin‑converting‑enzyme inhibitors, angiotensin 
II receptor blockers
ATC: C09
 Loop diuretics ATC: C03CA01
 Insulin ATC: A10A
 Metformin ATC A10BA02
 Sulfonylurea ATC: A10BB
 Thiazolide ATC: A10BG
 Dipeptidyl peptidase‑4 inhibitor ATC: A10BB
 Glucagon‑like peptide‑1 ATC: A10BG
 Sodium‑glucose co‑transporter‑2 ATC: A10BK
 Combination of two anti‑diabetic drugs Either a combination of metformin, sulfonylurea, thiazolidinedione, 
dipeptidyl peptidase‑4 inhibitor, sodium‑glucose cotrans‑
porter‑2 or glucagon‑like peptide‑1 receptor agonist
ATC: A10BD
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